INS and metabolic dysfunction-associated steatotic liver disease: Several studies have shown that the application of ASBT inhibitors can ameliorate high-fat diet-induced hepatic steatosis, reduce hepatic lipid accumulation, and improve insulin sensitivity in NAFLD mice (Rao et al., 2016; Ge et al., 2019).